DNA origami cages constrain individual proteins toward preferred orientations on electrodes, dramatically improving ...
Pfizer disclosed a patient death in a marstacimab hemophilia study, triggering a safety review and reassessment of surgical ...
Indian Defence Review on MSN
Scientists Just Flagged This Everyday Sweetener for Sharply Increasing Stroke and Heart Attack Risk
It’s in your favorite sugar-free snacks, backed by health claims, and approved by regulators. But scientists just uncovered ...
A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...
Investing.com -- A patient died after receiving Pfizer Inc.’s (NYSE:PFE) hemophilia drug Hympavzi, adding to challenges for ...
Company Continues to Broaden Leading Wound Product OfferingMARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc ...
Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseasesQfitlia, the first antithrombin-lowering therapy for hemophilia, ...
China NMPA approves Sanofi’s Qfitlia for haemophilia and Cablivi for acquired thrombotic thrombocytopenic purpura: Paris Friday, December 12, 2025, 09:00 Hrs [IST] The National ...
The National Medical Products Administration (NMPA) in China has approved Sanofi SA’s (NASDAQ: SNY) two medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi ...
India carries a heavy cardiometabolic burden of nearly 30%, intensified by early-onset diabetes, hypertension, dyslipidaemia, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback